Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion

This is a provisional clinical opinion (PCO) for chemotherapy-naive men with castration-resistant prostate cancer (CRPC). This PCO examines second-line hormonal therapy and provides recommendations on staging, treatment, follow-up, and palliative care for men with CRPC. Outcomes of interest include overall survival, adverse events, quality of life, and treatment efficacy (defined as response in prostate-specific antigen values).